Form 8-K OMNICELL, Inc For: Aug 20
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 20, 2015
OMNICELL, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-33043 |
|
94-3166458 |
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
590 E. Middlefield Road
Mountain View, CA 94043
(Address of principal executive offices, including zip code)
(650) 251-6100
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 20, 2015, Omnicell, Inc. (the Company) announced that Peter Kuipers, age 43, has been appointed Executive Vice President and Chief Financial Officer of the Company, effective August 24, 2015. A press release announcing the change in the Chief Financial Officer position is attached as Exhibit 99.1 hereto and incorporated herein by reference. From December 2014 to May 2015, Mr. Kuipers served as Senior Vice President and Chief Financial Officer of Quantcast Corp., a global technology company that specializes in digital audience measurement and real-time advertising. From May 2013 to December 2014, Mr. Kuipers served as Executive Vice President and Chief Financial Officer of The Weather Company, a media and global technology leader operating The Weather Channel, weather.com, wunderground.com and its professional services division WSI. From September 2009 to April 2013, Mr. Kuipers served in various financial management positions at Yahoo! Inc., a global internet technology company, most recently as Vice President, Finance-Americas. Prior to Yahoo!, Mr. Kuipers served in Senior Financial leadership roles at Altera Corp., General Electric Company and Akzo Nobel. He started his career with Ernst & Young in the Netherlands and Seattle, Washington. Mr. Kuipers received a Masters Degree in Economics and Business Administration from Maastricht University and is a Chartered Accountant in the Netherlands.
Mr. Kuipers will be compensated at an initial base salary of $370,000 per annum, and will receive, upon approval by the Companys Board of Directors or a committee thereof, (i) an option to purchase up to 37,500 shares of the Companys Common Stock at an exercise price equal to the fair market value of the Companys Common Stock on the date of grant, which option shall vest over a four-year period, with a one-year cliff and (ii) an award of 22,500 shares of restricted stock units, which will vest in equal increments every 6 months on June 15 and December 15 over a four-year vesting period. Mr. Kuipers also will be eligible to participate in the Omnicell 2010 Quarterly Executive Bonus Plan wherein he may receive cash bonuses of up to 50% of his annual base salary based on the achievement of Company and personal performance objectives, subject to changes at the discretion of the Company. Mr. Kuipers may also be eligible to participate, on a pro-rata basis, in the Companys 2015 Over Achievement Bookings Bonus, to be determined based on the overachievement of the Companys bookings.
In addition, Mr. Kuipers is eligible for certain severance benefits set forth in the Companys executive Change in Control Agreement and Amended and Restated Severance Benefits Plan, and indemnity protection under an indemnity agreement.
In connection with and effective upon Mr. Kuipers appointment, Robin G. Seim will step down from his role as the Companys Chief Financial Officer and will remain as the Companys Executive Vice President, International and Global Quality and Manufacturing.
The description of the compensation arrangements contained herein do not purport to be complete and are qualified in their entirety by reference to the complete text of the offer letter entered into by and between the Company and Mr. Kuipers, including any exhibits thereto, a copy of which will be filed as an exhibit to the Companys Quarterly Report on Form 10-Q for the period ending September 30, 2015.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit |
|
Description |
99.1 |
|
Press Release entitled Omnicell Appoints Peter Kuipers as Chief Financial Officer dated August 20, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
OMNICELL, INC. | |
|
| |
|
| |
Dated: August 20, 2015 |
By: |
/s/ Dan S. Johnston |
|
|
Dan S. Johnston, Executive Vice President, Chief Legal & Administrative Officer |
EXHIBIT INDEX
Exhibit |
|
Description |
99.1 |
|
Press Release entitled Omnicell Appoints Peter Kuipers as Chief Financial Officer dated August 20, 2015 |
Exhibit 99.1
Omnicell Appoints Peter Kuipers as Chief Financial Officer
Expansion of Executive Team Adds 20 Years of Financial Expertise within Technology and International Markets
Mountain View, Calif., August 20, 2015 Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced that Peter Kuipers has joined the company as Executive Vice President, Chief Financial Officer. Mr. Kuipers brings 20 years of financial and business strategy leadership experience in high tech, manufacturing, and international markets. As announced in February, current CFO Rob Seim now completes the transition to his new role as Executive Vice President, International and Global Quality & Manufacturing.
Peter offers a unique blend of industry experience that will make him a valuable addition to our executive team as we look to solidify our position as a leader in the U.S. and expand international opportunities, said Randall Lipps, Omnicell president, chairman, and CEO. Peters experience will help to advance the companys focus on growth through differentiated products, new markets, and acquisitions, he said.
Prior to joining Omnicell, Mr. Kuipers served as Senior Vice President and Chief Financial Officer at Quantcast Corporation, a world leader in applying the power of big data and analytics to digital audience measurement and advertising. Previously Mr. Kuipers served as Executive Vice President and CFO at The Weather Company (TWC), operating The Weather Channel, weather.com, wunderground.com and its professional services division WSI.
Prior to TWC, Mr. Kuipers served in various financial leadership roles at Yahoo!, including for the companys largest geographical region as Vice President of Finance for the Americas, a multibillion-dollar business, and led teams responsible for Financial Planning and Analysis, Business Finance, Accounting, and Reporting for the region across multiple product lines and channels. At Yahoo! he also previously served as Vice President of Finance for the Global Products division and as Vice President of Finance for International Regions.
Previously Mr. Kuipers served in senior financial leadership roles at Altera Corporation, General Electric Company, and Akzo Nobel. He started his career with Ernst & Young in the Netherlands and Seattle, Washington.
He holds a Masters Degree in Economics and Business Administration from the Maastricht University School of Business and Economics in the Netherlands. He is also a Chartered Accountant in the Netherlands.
Medication and supply management in health care is undergoing a transformation driven by the power of data and automation technology, said Mr. Kuipers. Omnicell is well positioned to provide industry-leading levels of quality and safety to medication management solutions globally and I am proud to be joining one of the industrys leading innovators.
As I move into a new role centered around our international markets, Im pleased to welcome Peter to the role of CFO, shared Rob Seim. In an age where international hospitals and health systems are looking to mirror best practices developed by hospitals in the U.S., Im excited to evaluate and meet the needs of potential customers abroad.
Since joining us in 2006 Rob has done a terrific job as our CFO, where he has led many of our efforts that resulted in a quadrupling of the revenue and growth of operating income from 6% to 15%. Were excited about his willingness to take on this expanded role that is core to our continued growth, and appreciate his ongoing commitment and dedication to Omnicell, said Mr. Lipps.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuumfrom the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
For more information about Omnicell, Inc. please visit www.omnicell.com.
Forward-Looking Statements
To the extent any statements contained in this release deal with information that is not historical, these statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to the occurrence of many events outside Omnicells control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such statements include, but are not limited to the success of Omnicells executive team, Omnicells U.S. strategy and Omnicells expansion of international opportunities. Risks that contribute to the uncertain nature of the forward-looking statements include our ability to take advantage of the growth opportunities in medication management across the spectrum of healthcare settings
from long term care to home care, unfavorable general economic and market conditions, risks to growth and acceptance of our products and services, including competitive conversions, and to growth of the clinical automation and workflow automation market generally, the potential of increasing competition, potential regulatory changes, the ability of the company to improve sales productivity to grow product bookings, to develop new products and to acquire and successfully integrate companies. These and other risks and uncertainties are described more fully in Omnicells most recent filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Omnicell undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
OMCL-G
###
Editors Notes:
1. All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the companys external website, omnicell.com.
2. Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
3. All other brand or product names may be trademarks or registered trademarks of their respective companies.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Omnicell (OMCL) Announces XT Amplify
- Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024
- Clarification of Details Regarding Oceansix's Engagement with RB Milestone Group LLC
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!